

# Influence of Flickering Light on the Retinal Vessels in Diabetic Patients

ALEKSANDRA MANDECKA, MD<sup>1</sup>  
 JENS DAWCZYNSKI, MD<sup>2</sup>  
 MARCUS BLUM, MD<sup>3</sup>  
 NICOLLE MÜLLER, DNUTR<sup>1</sup>  
 CHRISTOPH KLOOS, MD<sup>1</sup>

GUNTER WOLF, MD<sup>1</sup>  
 WALTHARD VILSER, MS<sup>4</sup>  
 HEIKE HOYER, MS<sup>5</sup>  
 ULRICH ALFONS MÜLLER, MD, MSC<sup>1</sup>

**OBJECTIVE** — Stimulation of the retina with flickering light increases retinal vessel diameters in humans. Nitric oxide is a mediator of the retinal vasodilation to flicker. The reduction of vasodilation is considered an endothelial dysfunction. We investigated the response of retinal vessels to flickering light in diabetic patients in different stages of diabetic retinopathy.

**RESEARCH DESIGN AND METHODS** — We studied 53 healthy volunteers, 68 type 1 diabetic patients, and 172 type 2 diabetic patients. The diameter of retinal vessels was measured continuously online with the Dynamic Vessel Analyzer (DVA). Diabetic retinopathy was classified using Early Treatment Diabetic Retinopathy Study criteria. Changes in vasodilation are expressed as percent change over baseline values.

**RESULTS** — After adjustments for age, sex, and antihypertensive treatment, the response of retinal arterioles to diffuse luminance flicker was significantly diminished in patients with type 1 diabetes compared with healthy volunteers. The vasodilation of retinal arterioles and venules decreased continuously with increasing stages of diabetic retinopathy. The retinal arterial diameter change was  $3.6 \pm 2.1\%$  in the control group,  $2.6 \pm 2.5\%$  in the no diabetic retinopathy group,  $2.0 \pm 2.7\%$  in the mild nonproliferative diabetic retinopathy (NPDR) group,  $1.6 \pm 2.2\%$  in the moderate NPDR group,  $1.8 \pm 1.9\%$  in severe NPDR group, and  $0.8 \pm 1.6\%$  in proliferative diabetic retinopathy group.

**CONCLUSIONS** — Flicker responses of retinal vessels are abnormally reduced in diabetic patients. This decreased response deteriorated with increasing stages of retinopathy. The response was already reduced before clinical appearance of retinopathy. The noninvasive testing of retinal autoregulation with DVA might prove to be of value in early detection of diabetic vessel pathological changes.

*Diabetes Care* 30:3048–3052, 2007

**H**yperglycemia, dyslipidemia, hypertension, and diabetes duration are the main risk factors for the development and progression of diabetic retinopathy (1–3). However, the exact pathogenesis of this disease remains incompletely understood. There is evidence that endothelial dysfunction may play an

important role in the pathogenesis of diabetic retinopathy (4). Markers of endothelial dysfunction such as soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1 are elevated in patients with diabetic retinopathy. However, the association between markers of endothelial dysfunction

and diabetic retinopathy has not always been consistent, presumably because of the considerable biological variation in the measurement of such markers (5). Therefore, the use of other parameters is desirable to assess the regulation ability of retinal vessels.

Endothelial cells regulate vascular reactivity by responding to mechanical forces and neurohumoral mediators with the release of a variety of relaxing and contracting factors (6). One of the most important endothelium-derived vasodilators is nitric oxide (NO), the bioavailability of which is decreased in diabetes (7). In addition, NO appears to be a mediator of the retinal vasodilator response to flicker light (8). Several human studies showed an increase in retinal vessel diameter during stimulation with diffuse luminance flicker (8–10).

In the current study, we investigated the response of retinal arterial and venous vessels to flickering light in patients with diabetes. All retinal vessels are by definition vessels of microcirculation. For our purpose, a recently developed provocation test was used. Diffuse luminance flicker was applied, and retinal vessel diameters were measured with a Dynamic Vessel Analyzer (DVA) (Imedos, Jena, Germany). We determined the endothelium-derived vasodilation of retinal arteries in different stages of diabetic retinopathy.

## RESEARCH DESIGN AND METHODS

The study was performed on a group of healthy volunteers and type 1 and 2 diabetic patients who were being treated in a large outpatient diabetes clinic at a tertiary university hospital. A total of 53 healthy subjects, 68 patients with type 1 diabetes, and 172 patients with type 2 diabetes were investigated. All subjects were of Caucasian origin. Of the diabetic patients, 83.3% were treated with insulin, 31.6% with oral antidiabetic agents, and 80.4% with antihypertensive drugs. All examinations were performed after the patients had received oral and written information about the study and had given their consent to participate. The examinations were performed in accordance with the Declaration of Helsinki and were approved by the local ethics committee.

From the <sup>1</sup>Department of Internal Medicine III, Friedrich-Schiller University, Jena, Germany; the <sup>2</sup>Department of Ophthalmology, Friedrich-Schiller University, Jena, Germany; the <sup>3</sup>Department of Ophthalmology, Helios Klinikum, Erfurt, Germany; <sup>4</sup>IMEDOS, Jena, Germany; and the <sup>5</sup>Institute of Medical Statistics, Computer Sciences and Documentation, Friedrich-Schiller-University, Jena, Germany.

Address correspondence and reprint requests to Aleksandra Mandacka, Department of Internal Medicine III, Friedrich-Schiller University, Bachstrasse 18, 07743, Jena, Germany. E-mail: aleksandra.mandacka@med.uni-jena.de.

Received for publication 15 May 2007 and accepted in revised form 22 August 2007.

Published ahead of print at <http://care.diabetesjournals.org> on 28 August 2007. DOI: 10.2337/dc07-0927.

**Abbreviations:** DVA, Dynamic Vessel Analyzer; ETDRS, Early Treatment Diabetic Retinopathy Study; NPDR, nonproliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

© 2007 by the American Diabetes Association.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

**Table 1—Characteristics of the study groups**

Parameter	Control group	Type 1 diabetes	Type 2 diabetes
n	53	68	172
Sex			
Male	14 (26)	30 (44)*	97 (56)*
Female	39 (74)	38 (56)	75 (44)
Age (years)	41.9 ± 16.6	47.5 ± 15.3*	61.7 ± 10.1*
Mean arterial pressure (mmHg)	87.8 ± 8.5	92.9 ± 8.2*	100.7 ± 9.9*
A1C (%)	—	7.9 ± 1.2	7.4 ± 1
Duration of diabetes (years)	—	17.7 ± 10.3	11.4 ± 7.8
Antihypertensive treatment	0 (0)	33 (49)*	156 (92)*
Missing data	2	1	2

Data are n (%) or means ± SD. A1C normal range: 4.6–5.9. \*Significantly different compared with the control group.

In all subjects, the left eye was studied. Volunteers were taking no medication at the time of the study. The healthy participants were nonsmokers, had no previous history of arterial hypertension or metabolic or cardiovascular disease, and did not receive any medication on prescription. All subjects had no history of epilepsy or ocular disease other than diabetic retinopathy and carotid artery obstruction and were nonsmokers. Every patient had undergone measurement of intraocular pressure within 1 year before enrollment. Patients with increased intraocular pressure were excluded. All subjects were asked to refrain from use of alcohol, nicotine, and caffeine for at least 1 h before the examination.

The clinical data of the patients examined are shown in Table 1. Diabetic patients were significantly older and had higher mean arterial blood pressure compared with the healthy control group.

### Study protocol

At the start of the study, fundus examination was performed after induction of mydriasis with 1% tropicamide eye drops. Diabetic retinopathy was classified using Early Treatment Diabetic Retinopathy Study (ETDRS) criteria (11) as no diabetic retinopathy (ETDRS level 10), mild nonproliferative diabetic retinopathy (NPDR) (ETDRS level ≥20), moderate NPDR (ETDRS level ≥43), severe NPDR (ETDRS level ≥53), and proliferative diabetic retinopathy (PDR) (ETDRS level ≥61).

The DVA was used for digital fundus imaging for conventional fundus examinations and for retinal vessel analysis. Ret-

inal vessel analysis with the DVA allows noninvasive diagnosis of microvascular function by measuring the diameter of arterial and venous retinal vessels continuously 25 times/s and by using stimulation tests of vessel functions. By interrupting of the green measuring light, the DVA generates flicker light with a frequency of 12.5 Hz and with a bright-to-dark ratio of 25:1 for a stimulation test. Diameter responses can be recorded by use of flicker light periods during the vessel diameter measurements. The dilatation of vessel diameter caused by flickering light can be used as a function diagnostic parameter for the endothelium-derived vasodilation. Details of the DVA and the processes of diameter measurements and flicker stimulations are described elsewhere (12–15).

After the baseline vessel diameter was measured for 50 s, provocation with flicker light was performed for 20 s, and the response was observed for 80 s after the end of the flicker exposure. The cycle

was then repeated two times. An arterial segment of ~1.5 mm was evaluated in each eye. Selection criteria for the segment were location within a circular area of two disc diameters, no crossing or bifurcation in the measuring segment, curvature of not >30°, a distance to neighboring vessels of at least one vessel diameter, and sufficient contrast to the surrounding fundus. The position of the vessel edges, the vessel course, the vessel diameter, and correction for ocular movements were calculated automatically online.

### Blood pressure measurements

The mean systemic arterial blood pressures of the groups are listed in Table 1. No significant increase in blood pressure occurred during the examination. The mean arterial blood pressure (mean RR) was calculated as mean RR = RR diastole + 1/3 \* (RR systole – RR diastole) mmHg, where RR systole is systolic blood pressure and RR diastole is diastolic blood pressure.

### Statistical analyses

Changes in ocular hemodynamic parameters are expressed as the percent change over baseline values. Retinal vessel diameters were calculated as an average of the last 30 s of the baseline of each cycle. Vessel diameter during flicker was calculated as an average of the last 3 s of light stimulation and the following 3 s after stimulation. All variables obtained were described by adequate statistical measures. Differences between groups were statistically evaluated by *t* test, the Mann-Whitney *U* test, or  $\chi^2$  test as appropriate. To adjust for imbalances of age, sex, and antihypertensive treatment, ANCOVA was applied. Contrasts were defined to test differences between type 1 or type 2 diabetic patients compared with the control group and to analyze the linear trend of

**Table 2—Mean diameter change of retinal arteries and veins to flicker in healthy subjects and diabetic patients**

Parameter	Control group	Type 1 diabetes	Type 2 diabetes
Arterial vasodilation (%)	3.6 ± 2.0	2.1 ± 2.3	2.2 ± 2.5
<i>P</i> *		<0.001	<0.001
Arterial vasoconstriction (%)	–1.4 ± 1.7	–1.0 ± 1.7	–0.6 ± 1.4
<i>P</i>		0.135	0.001
Venous diameter change (%)	4.5 ± 2.4	4.0 ± 2.3	3.5 ± 2.1
<i>P</i>		0.212	0.005

Data are means ± SD. \**P* values from unadjusted comparison with control group.

vasodilatation depending on the severity of diabetic retinopathy.  $P < 0.05$  was considered to be statistically significant. Statistical analysis was performed with SPSS (version 13.0.1; SPSS, Chicago, IL).

**RESULTS**— In retinal arterioles, the response to stimulation with luminance flicker was diminished in diabetic patients compared with healthy volunteers (Table 2). In healthy control subjects, flicker stimulation increased the retinal arterial diameter by  $3.6 \pm 2.0\%$ , in type 1 diabetic patients by  $2.1 \pm 2.3\%$ , and in type 2 diabetic patients by  $2.2 \pm 2.5\%$ . The response was significantly decreased regardless of type of diabetes. The constriction of the retinal arteries, as well as the response of retinal venous diameters, was also diminished in diabetic patients compared with control subjects, but differences were significant only in type 2 diabetic patients compared with control subjects.

**Association of retinal vessel flicker response with age and duration of the disease**

Age and duration of diabetes were significantly associated with arterial diameter response in diabetic subjects. The vasodilation of the arteries decreased significantly with increasing age and duration of disease. With increasing age, there was a tendency toward smaller dispersion of the dilation.

The age versus arterial diameter change scatterplot shows a decreasing flicker response and increasing dispersion of the measured values in subjects of middle to advanced age. The small coefficient of correlation ( $r = 0.22$ ) indicates a weak correlation between the two parameters (data not shown).

To account for confounding by age, by antihypertensive treatment, and probably by sex, vasodilatation was further analyzed by ANCOVA (Table 3). After adjustment, the difference between diabetic patients and the control group remained significant for the arterial diameter change in type 1 diabetic patients. The difference in venous diameter change in type 2 diabetic patients compared with control subjects was more pronounced after adjustment but failed to reach statistical significance at the global significance level.

**Table 3—Age-, antihypertensive treatment-, and sex-adjusted mean differences of diameter change comparing type 1 and type 2 diabetic patients with the control group of healthy subjects**

Group	Adjusted difference (%)*	95% CI	P value (global test)†
<b>Arterial vasodilatation</b>			
Control	Reference		0.024
Type 1 diabetes	-1.1	-2.0 to -0.2	
Type 2 diabetes	-0.3	-1.4 to 0.8	
<b>Arterial vasoconstriction</b>			
Control	Reference		0.823
Type 1 diabetes	0.2	-0.4 to 0.9	
Type 2 diabetes	0.2	-0.5 to 0.9	
<b>Venous diameter change</b>			
Control	Reference		0.063
Type 1 diabetes	-0.7	-1.6 to 0.2	
Type 2 diabetes	1.2	-2.2 to -0.2	


Groups: type 1 diabetic ( $n = 68$ ), type 2 diabetic ( $n = 170$ ), and control ( $n = 53$ ). \*Difference<sub>(type 1-control)</sub> or difference<sub>(type 2-control)</sub>. †P values from covariance analyses; deviation from symmetry of CIs because of rounding.

**Association of retinal vessel flicker response with mean arterial blood pressure and A1C**


There was no significant association between arterial retinal flicker response and mean arterial blood pressure or A1C in diabetic patients (multiple regression analyses). The flicker response of retinal arteries in diabetic patients deteriorated but not significantly with increasing A1C (data not shown).

**Retinal vessel flicker response in different stages of diabetic retinopathy**

The retinal arterial diameter changes were  $3.6 \pm 2.1$ ,  $2.6 \pm 2.5$ ,  $2.0 \pm 2.7$ ,  $1.6 \pm 2.2$ ,  $1.8 \pm 1.9$ , and  $0.8 \pm 1.6\%$  in the control group ( $n = 53$ ), no diabetic retinopathy group ( $n = 145$ ), mild NPDR group ( $n = 36$ ), moderate NPDR group ( $n = 27$ ), severe NPDR group ( $n = 18$ ), and PDR group ( $n = 14$ ), respectively



**Figure 1—Arterial diameter changes at stages of diabetic retinopathy (DR).**



**Figure 2**—Venous diameter changes at stages of diabetic retinopathy (DR).

(Fig. 1). There was a significant trend of decreasing retinal arterial response along the groups (age-, antihypertensive treatment-, and sex-adjusted trend test  $P = 0.002$ ). The venous diameter changes were  $4.6 \pm 2.4$ ,  $3.9 \pm 2.3$ ,  $3.7 \pm 2.2$ ,  $3.5 \pm 2.1$ ,  $2.7 \pm 2.2$ , and  $3.1 \pm 2.0\%$  in the control group, no diabetic retinopathy group, mild NPDR group, moderate NPDR group, severe NPDR group, and PDR group, respectively (Fig. 2). The adjusted retinal venous response was also significantly decreased (trend test  $P = 0.007$ ). No significant trend could be observed for constriction of the retinal arteries.

**CONCLUSIONS**— In this in vivo study, we compared endothelial function under physiological flow conditions and in the presence of the diabetic milieu. Noninvasive testing of the function of autoregulation of retinal arterioles is possible with the DVA (13–16). There is much evidence for abnormal autoregulation of retinal vessels in diabetic patients. Using the laser Doppler technique, Grunwald et al. (17) reported reduced retinal arterial and venous blood velocity as well as enlarged retinal veins in patients with diabetes with background retinopathy. Moreover, retinal blood flow is reduced in patients with diabetes with no diabetic retinopathy compared with patients with-

out diabetes (18,19). There is also evidence that the early stages of diabetic retinopathy are associated with increased retinal blood flow and retinal vasodilation, abnormal retinal vascular response to hyperoxia, and abnormal retinal autoregulation (20–23). The intrinsic abnormality in diabetic retinopathy appears to be endothelial cell dysfunction (24–26). The present study focuses on the retinal diameter changes of major temporal retinal vessels of diabetic patients to diffuse luminance flicker. In humans, the flicker light-induced vasodilation is mediated by NO (27). Hence, this test could be used as an estimate of the capacity of endothelial cells of retinal vessels to release NO in response to a physiological stimulus in disease states.

We demonstrated that the retinal vessel flicker response is diminished in diabetic patients compared with that in normal control participants. This finding is in agreement with a previous report indicating reduced flicker response in type 1 diabetic patients (28). We have also reported abnormal autoregulation in patients with type 2 diabetes.

The present study demonstrates that the vasodilation of retinal arteries and veins under the flickering light decreases continuously with increasing stages of diabetic retinopathy. Furthermore, autoregulation was also found to be abnormal

in diabetic patients without retinopathy and deteriorated continuously in patients with retinopathy, suggesting that the disturbance is involved in the disease pathogenesis. The venous retinal response was reduced in diabetic patients without any visible signs of diabetic retinopathy compared with the control group. This finding is in agreement with several previous reports indicating impairment of blood flow regulation in the retina before the clinical appearance of retinopathy (21, 29). In our study we showed an association between flicker response and age; however, the coefficient of correlation was weak, which is in agreement with previous reports (30). For example, Jeppesen et al. (31) reported significantly reduced diameter response in normal individuals aged >40 years.

Most of the diabetic patients were receiving antihypertensive treatment at the time of testing. To rule out the possible confounding effect of drugs, we adjusted the data for imbalances of antihypertensive medication. The adjusted response of retinal vessels to flickering light decreased significantly with increasing stages of diabetic retinopathy. This finding suggests that diabetes has a deteriorating effect per se on the flow regulation in response to flicker stimulation.

In summary, this study demonstrated a decreased retinal vessel flicker response in patients with diabetes. This decreased response deteriorated with increasing stages of diabetic retinopathy. Indeed, the response was already low before the clinical appearance of retinopathy. The predictive value of this method for detecting diabetic patients at risk for the development of diabetic retinopathy needs to be tested with long-term observational studies.

## References

1. Van Leiden HA, Dekker JM, Moll AC, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD, Polak BC: Blood pressure, lipids and obesity are associated with retinopathy: the Hoorn study. *Diabetes Care* 25:1320–1325, 2002
2. Nagi DK, Pettitt DJ, Bennett PH, Klein R, Knowler WC: Diabetic retinopathy assessed by fundus photography in Pima Indians with impaired glucose tolerance and NIDDM. *Diabetes Med* 14:449–456, 1997
3. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley LE, Matthews DR: UKPDS 50: risk factors for incidence and progression of retinopathy in



- type II diabetes over 6 years from diagnosis. *Diabetologia* 44:156–163, 2001
4. Stehouwer CD, Lambert J, Donker AJ, van Hinsbergh VW: Endothelial dysfunction and pathogenesis of diabetic angiopathy. *Cardiovasc Res* 34:55–68, 1997
  5. van Hecke MV, Dekker JM, Nijpels G, Moll AC, Heine RJ, Bouter LM, Polak BCP, Stehouwer CDA: Inflammation and endothelial dysfunction are associated with retinopathy: the Hoorn study. *Diabetologia* 48:1300–1306, 2005
  6. Furchgott RF, Vanhoutte PM: Endothelium-derived relaxing and contracting factors. *FASEB J* 3:2007–2018, 1989
  7. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RA, Warnholtz A, Meinertz T, Griendling K, Harrison DG, Forstermann U, Munzel T: Mechanisms underlying endothelial dysfunction in diabetes mellitus. *Circ Res* 88:E14–E22, 2001
  8. Dorner GT, Garhofer G, Kiss B, Polska E, Polak K, Riva CE, Schmetterer L: Nitric oxide regulates retinal vascular tone in humans. *Am J Physiol* 285:H631–H636, 2003
  9. Polak K, Schmetterer L, Riva CE: Influence of flicker frequency on flicker induced changes of retinal vessel diameters. *Invest Ophthalmol Vis Sci* 43:2721–2726, 2002
  10. Dorner GT, Garhofer G, Huemer KH, Riva CE, Woltz M, Schmetterer L: Hyperglycemia affects flicker-induced vasodilation in the retina of healthy subjects. *Vis Res* 43:1495–500, 2003
  11. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. *Arch Ophthalmol* 113:36–51, 1995
  12. Vilser W, Nagel E, Fuhrmann G, Riemer T: Retinale Gefaessanalyse-Neue Moeglichkeiten zur Untersuchungen von Netzhaut-gefaessen. In *Fortbildung Glaukom Band 3*. Schmidt KG, Pillunat LE, Eds. Stuttgart, Enke Verlag, 2000, p. 73–91
  13. Polak K, Dorner G, Kiss B, Polska E, Findl O, Rainer G, Eichler HG, Schmetterer L: Evaluation of the Zeiss retinal vessel analyzer. *Br J Ophthalmol* 84:1285–1290, 2000
  14. Blum M, Bachmann K, Wintzer D, Riemer T, Vilser W, Strobel J: Noninvasive measurement of the Bayliss effect in retinal autoregulation. *Graefes Arch Clin Exp Ophthalmol* 237:296–300, 1999
  15. Blum M, Bachmann K, Pietscher S, Braeuer-Burchhardt C, Vilser W, Strobel J: [Online measurement of retinal artery branches in type II diabetic patients. Initial clinical trials before and after laser coagulation]. *Ophthalmologe* 94:724–727, 1997 (article in German)
  16. Vilser W, Nagel E, Lanzl I: Retinal vessel analysis—new possibilities. *Biomed Tech (Berl)* 47:682–685, 2002
  17. Grunwald JE, Riva CE, Sinclair SH: Laser Doppler velocimetry study of retinal circulation in diabetes mellitus. *Arch Ophthalmol* 104:991–996, 1986
  18. Grunwald JE, Brucker AJ, Schwartz SS, Braunstein SN, Baker L, Petrig BL, Riva CE: Diabetic glycemic control and retinal blood flow. *Diabetes* 39:602–607, 1990
  19. Bursell SE, Clermont AC, Kinsley BT, Simonson DC, Aiello LM, Wolpert UA: Retinal blood flow changes in patients with insulin-dependent diabetes mellitus and no diabetic retinopathy. *Invest Ophthalmol Vis Sci* 37:886–897, 1996
  20. Falck A, Laatikainen L: Retinal vasodilation and hyperglycaemia in diabetic children and adolescents. *Acta Ophthalmol Scand* 73:119–124, 1995
  21. Grunwald JE, DuPont J, Riva CE: Retinal haemodynamics in patients with early diabetes mellitus. *Br J Ophthalmol* 80:327–331, 1996
  22. Patel V, Rassam SM, Chen HC, Kohner EM: Oxygen reactivity in diabetes mellitus: effect of hypertension and hyperglycaemia. *Clin Sci* 86:689–695, 1994
  23. Rassam SM, Patel V, Kohner EM: The effect of experimental hypertension on retinal vascular autoregulation in humans: a mechanism for the progression of diabetic retinopathy. *Exp Physiol* 80:53–68, 1995
  24. Colwell JA, Winocour PD, Lopes-Virella M, Haluschka PV: New concepts about the pathogenesis of atherosclerosis in diabetes mellitus. *Am J Med* 75:67–80, 1983
  25. Kohner EM, Porta M: Vascular abnormalities in diabetes and their treatment. *Trans Ophthalmol Soc UK* 100:440–444, 1980
  26. Almer LA, Pandolfi M: Fibrinolysis and diabetic retinopathy. *Diabetes* 25 (Suppl. 2):807–810, 1976
  27. Delles C, Michelson G, Harazny J, Oehmer S, Hilgers KF, Schmieder RE: Impaired endothelial function of the retinal vasculature in hypertensive patients. *Stroke* 35:1289–1293, 2004
  28. Garhofer G, Zawinka C, Resch H, Kothly P, Schmetterer L, Dorner GT: Reduced response of retinal vessel diameters to flicker stimulation in patients with diabetes. *Br J Ophthalmol* 88:887–891, 2004
  29. Fekete GT, Buzney SM, Ogasawara H, Fujio N, Goger DG, Spack NP, Gabbay KH: Retinal circulatory abnormalities in type 1 diabetes. *Invest Ophthalmol Vis Sci* 35:2968–2975, 1994
  30. Nagel E, Vilser W, Lanzl I: Age, blood pressure, and vessel diameter as factors influencing the arterial retinal flicker response. *Invest Ophthalmol Vis Sci* 45:1486–1492, 2004
  31. Jeppesen P, Gregersen PA, Bek T: The age-dependent decrease in the myogenic response of retinal arterioles as studied with the Retinal Vessel Analyzer. *Graefes Arch Clin Exp Ophthalmol* 242:914–919, 2004